Almac has completed its knowledge transfer partnership with Belfast's Queens University, a pairing designed to boost the CDMO's biocatalysis business.
Thanks to the two-year collaboration, Almac can deliver a fully integrated fermentation, optimization and bioproduct service to its customers, the company says. Through the process, Almac developed, improved and embedded new bioprocesses with the aid of Queens' academics, Almac Biocatalysis and Radiolabelling chief Tom Moody said in a statement.
"Not only have we further strengthened our long-standing relationship with Queens University, but we have also increased our service offering within the biocatalysis field to our clients, thus allowing us to compete in an area which was previously beyond our reach," Moody said.
The partnership received the highest grade of outstanding from the KTP Grading Panel, and Moody said its success is a testament both to Almac's team and Queens University's dedication.
The Queens KTP follows Almac's October deal with DSM Pharmaceutical for applied biocatalysis, pooling their resources in the field to give each's clients access to their communal enzyme expertise. Almac has said the partnership will cut costs and speed up processing timelines from preclinical development to commercial manufacturing.
- read Almac's announcement